Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Dionysios Ktenas"'
Autor:
Dimitrios Alexopoulos, Vassiliki-Maria Dragona, Charalampos Varlamos, Dionysios Ktenas, Ioannis Lianos, Sotirios Patsilinakos, Dimitrios Sionis, Ioannis Zarifis, Theodora Bampali, Leonidas Poulimenos, Emmanouil Skalidis, Evangelos Pissimisis, Athanasios Trikas, Ioannis Tsiafoutis, Nickolaos Kafkas, Christoforos Olympios, Dimitrios Tziakas, Antonios Ziakas, Vassilis Voudris, Ioannis Kanakakis, Costas Tsioufis, Periklis Davlouros, Despoina-Rafailia Benetou
Publikováno v:
Journal of cardiovascular pharmacology.
GReek-AntiPlatElet Atrial Fibrillation (GRAPE-AF) registry is a multicenter, observational, non-interventional study of AF patients undergoing PCI. Primary endpoint included clinically significant bleeding rate at 12 months between different antithro
Autor:
Antonios Ziakas, Emmanouil Skalidis, Evangelos Pisimisis, Theodora Bampali, Ioannis Lianos, Dimitrios Varvarousis, Despoina-Rafailia Benetou, Christos Mantis, Periklis Davlouros, Grape-Af investigators, Dimitrios Alexopoulos, Michael Koutouzis, John Zarifis, John Kanakakis, Dionysios Aravantinos, Ioannis Tsiafoutis, Dionysios Ktenas, Charalampos Varlamos
Publikováno v:
Cardiovascular Drugs and Therapy. 35:11-20
Patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) are a high-risk subset of patients, whose optimal antithrombotic treatment strategy, involving a combination of anticoagulant and antiplatelet agents, has not
Autor:
Despoina-Rafailia, Benetou, Charalampos, Varlamos, Dionysios, Ktenas, Ioannis, Tsiafoutis, Michael, Koutouzis, Theodora, Bampali, Christos, Mantis, John, Zarifis, Emmanouil, Skalidis, Dionysios, Aravantinos, Dimitrios, Varvarousis, Ioannis, Lianos, John, Kanakakis, Evangelos, Pisimisis, Antonios, Ziakas, Periklis, Davlouros, Dimitrios, Alexopoulos
Publikováno v:
Cardiovascular drugs and therapy. 35(1)
Patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) are a high-risk subset of patients, whose optimal antithrombotic treatment strategy, involving a combination of anticoagulant and antiplatelet agents, has not